Glancy Prongay & Murray LLP ("GPM") continues its investigation on behalf of Cancer Genetics, Inc. ("Cancer Genetics" or the "Company) (NASDAQ: CGIX) investors concerning the Company and its officers' possible violations of federal securities laws. To obtain information or aid in the investigation, please visit the Cancer Genetics investigation page on our website at www.glancylaw.com/case/cancer-genetics-inc. On April 2, 2018, the Company reported that following the departure of its former CEO, it undertook a "comprehensive and extensive review" of its strategy and organization. As a result, the Company recorded a bad debt expense of $4.4 million and wrote off $1.8 million of its accounts receivable in the fourth quarter of 2017, largely related to "collection issues" with respect to the accounts receivable recorded subsequent to the Company's 2015 acquisition of Response Genetics Inc. The Company further disclosed that it "had a Material Weakness in Internal Controls Over Financial Reporting at December 31, 2017" and that its 2017 annual report would contain a going concern qualification. On this news, Cancer Genetics' share price fell $0.55 per share, or 33.3%, thereby injuring investors. Follow us for updates on Twitter: twitter.com/GPM_LLP. If you purchased Cancer Genetics securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to email@example.com, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.